Table 4 Comparison of triptan overuse in one quarter and in two or more quarters of 2007
From: Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data
Overuse in 1 quarter n = 886 | Overuse in ≥2quarters n = 1084 | Statistics p-value | |||
|---|---|---|---|---|---|
Triptan DDD/year | |||||
Median | 80 | 132 | < 0.001# | ||
Lower quartile | 64 | 110.3 | |||
Upper quartile | 90 | 162 | |||
Range | 30–132 | 60–762 | |||
Age (years) | |||||
Median | 47 | 48 | < 0.001# | ||
Lower quartile | 39 | 41 | |||
Upper quartile | 54 | 56 | |||
Range | 18–87 | 19–95 | |||
Age group (years) | n | % | n | % | |
18–35 | 153 | 17.3 | 139 | 12.8 | 0.002§ |
36–50 | 427 | 48.2 | 491 | 45.3 | |
51–65 | 245 | 27.7 | 351 | 32.4 | |
66–99 | 61 | 6.9 | 103 | 9.5 | |
Sex | 0.761 | ||||
Female | 731 | 82.5 | 900 | 83 | |
Male | 155 | 17.5 | 184 | 17 | |